Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.10.2019 | short review | Ausgabe 4/2019 Open Access

memo - Magazine of European Medical Oncology 4/2019

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

The best of ASCO 2019

memo - Magazine of European Medical Oncology > Ausgabe 4/2019
Christoph Suppan, Marija Balic
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2019

memo - Magazine of European Medical Oncology 4/2019 Zur Ausgabe